Home

Moderna, Inc. - Common Stock (MRNA)

28.14
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 31st, 8:43 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close28.14
Open-
Bid28.04
Ask28.10
Day's RangeN/A - N/A
52 Week Range23.15 - 56.70
Volume246,830
Market Cap10.95B
PE Ratio (TTM)-3.737
EPS (TTM)-7.5
Dividend & YieldN/A (N/A)
1 Month Average Volume10,673,504

Chart

About Moderna, Inc. - Common Stock (MRNA)

Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More

News & Press Releases

Moderna Ignites Biotech Sector with Deal Talk Surge Amidst Broader Healthcare Woes
October 30, 2025 – While the broader S&P 500 Healthcare sector navigated a day of mixed to negative performance, a singular beacon of optimism emerged from the biotechnology landscape today as Moderna (NASDAQ: MRNA) witnessed an extraordinary surge in its stock price. Shares of the mRNA vaccine pioneer jumped by
Via MarketMinute · October 30, 2025
Discover which S&P500 stocks are making waves on Thursday.chartmill.com
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · October 30, 2025
Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Dealstocktwits.com
According to a report from Seeking Alpha, citing Stat News, Moderna has held talks with at least one large drugmaker.
Via Stocktwits · October 30, 2025
Thursday's session: top gainers and losers in the S&P500 indexchartmill.com
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · October 30, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · October 30, 2025
Is Moderna Inc Gaining or Losing Market Support?benzinga.com
Via Benzinga · October 30, 2025
1 S&P 500 Stock to Research Further and 2 We Find Risky
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · October 30, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Via Chartmill · October 28, 2025
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the market. While specific daily performance metrics remain unreleased, today's trading likely saw the sector reacting to a
Via MarketMinute · October 27, 2025
Integer Holdings (ITGR) Shares Plunge 31.4% as Slower New Product Adoption and Revised Guidance Rock Investor Confidence
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares plummeting a staggering 31.4%. The significant sell-off came despite the company reporting strong third-quarter 2025 earnings that largely met or exceeded
Via MarketMinute · October 23, 2025
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees.
Via ACCESS Newswire · October 23, 2025
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infectionbenzinga.com
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.
Via Benzinga · October 23, 2025
Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dustinvestors.com
The company is scrapping its study in congenital CMV after the vaccine proved just 6% to 23% effective.
Via Investor's Business Daily · October 23, 2025
Wondering what's happening in today's S&P500 pre-market session?chartmill.com
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.
Via Chartmill · October 23, 2025
Moderna to Host Investor Event - Analyst Day
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.
Via ACCESS Newswire · October 23, 2025
Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burnstocktwits.com
The biotech will continue testing the vaccine in bone marrow transplant patients, where CMV reactivation can cause serious complications, and said no safety concerns were identified.
Via Stocktwits · October 23, 2025
Global Economic Freedom in Retreat: A Four-Year Decline Signals Looming Market Shifts
Washington D.C., October 22, 2025 – The world stands at a critical juncture as the 2025 Economic Freedom of the World index, prominently released by the Fraser Institute in collaboration with the Cato Institute, reveals an alarming and unprecedented trend: a decline in global economic freedom for four consecutive years.
Via MarketMinute · October 22, 2025
What's going on in today's after hours session: S&P500 moverschartmill.com
Discover the top S&P500 movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · October 22, 2025
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Company to discontinue development of mRNA-1647 in congenital CMV
Via ACCESS Newswire · October 22, 2025
Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.fool.com
The biotech's innovative qualities will come in handy.
Via The Motley Fool · October 22, 2025
Should You Buy Moderna Right Now?fool.com
Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.
Via The Motley Fool · October 22, 2025
Wellgistics And DataVault Team Up To Transform Prescription Trackingbenzinga.com
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.
Via Benzinga · October 22, 2025
These 3 Beaten-Down Healthcare Stocks Could Have Farther to Fallfool.com
Don't try to catch a falling surgical knife.
Via The Motley Fool · October 21, 2025
Dow Jumps More Than 500 Points Ahead Of Earnings: Investor Fear Eases, Greed Index Remains In 'Fear' Zonebenzinga.com
U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close higher, with Fear & Greed Index at 30.3.
Via Benzinga · October 21, 2025
Small Caps Rally As Credit Fears Ease, Gold Rebounds To $4,350: What's Moving Markets Monday?benzinga.com
Via Benzinga · October 20, 2025